ColorectalArchives
The impact of KRAS mutations on risk of venous thromboembolism recurrence in patients with metastatic colorectal cancer
Colorectal 5 min.
Multiple studies have explored the association between different cancer types and the risk of venous thromboembolism (VTE) [1, 2–3]. Generally, aggressive cancers, marked by short survival times and early metastatic spread, are linked to a higher incidence of venous thrombosis [4]. Although colorectal...
Does adjuvant chemotherapy result in poorer health-related quality of life among colorectal cancer patients? A longitudinal multisite observational study in Singapore
Colorectal 5 min.
Colorectal cancer (CRC) is one of the most prevalent cancers, with nearly two million incident cases globally in 2018 [1]. Surgery remains the primary treatment for most patients presenting with potentially curable CRC [2, 3]. Following surgery, patients with more advanced cancers usually undergo adjuvant...
Analysis of extracellular vesicles of frequently used colorectal cancer cell lines
Colorectal 7 min.
Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide, with an estimated 1.93 million new cases diagnosed in 2022 alone [1]. This statistic stresses the urgent need for the development of more effective diagnostic and therapeutic strategies, and also for a deeper...
Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
Colorectal 5 min.
Colorectal cancer (CRC) is the leading cause of death worldwide and the most commonly diagnosed gastrointestinal cancer [1, 2]. Approximately 10% of CRC cases have a BRAF mutation, with the V600E mutation being the most common type. CRCs with BRAF mutations are generally associated with a poor prognosis...
